Filter

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 5 of 5 items for :

  • "erlotinib" x
Clear All
Giulia Bresciani Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Giulia Bresciani in
Google Scholar
PubMed Close
,
Angeliki Ditsiou Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Angeliki Ditsiou in
Google Scholar
PubMed Close
,
Chiara Cilibrasi Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Chiara Cilibrasi in
Google Scholar
PubMed Close
,
Viviana Vella Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Viviana Vella in
Google Scholar
PubMed Close
,
Federico Rea Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Federico Rea in
Google Scholar
PubMed Close
,
Marco Schiavon Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Marco Schiavon in
Google Scholar
PubMed Close
,
Narciso Giorgio Cavallesco Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

Search for other papers by Narciso Giorgio Cavallesco in
Google Scholar
PubMed Close
,
Georgios Giamas Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Georgios Giamas in
Google Scholar
PubMed Close
,
Maria Chiara Zatelli Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed Close
, and
Teresa Gagliano Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Teresa Gagliano in
Google Scholar
PubMed Close

therapeutic targets in the treatment of BP-NENs. Moreover, we have also assessed whether other RTK inhibitors, erlotinib and linsitinib, could be effective in malignancy management. Materials and methods Drugs and chemicals Sunitinib, erlotinib and

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0192
Volume/Issue:
Volume 8: Issue 6
Open access
Carina Hasenoehrl Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Graz, Austria

Search for other papers by Carina Hasenoehrl in
Google Scholar
PubMed Close
,
Gert Schwach Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Graz, Austria

Search for other papers by Gert Schwach in
Google Scholar
PubMed Close
,
Nassim Ghaffari-Tabrizi-Wizsy Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Graz, Austria
SFL Chicken CAM Lab, Institute of Pathophysiology and Immunology, Medical University of Graz, Graz, Austria

Search for other papers by Nassim Ghaffari-Tabrizi-Wizsy in
Google Scholar
PubMed Close
,
Robert Fuchs Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Graz, Austria

Search for other papers by Robert Fuchs in
Google Scholar
PubMed Close
,
Nadine Kretschmer Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria

Search for other papers by Nadine Kretschmer in
Google Scholar
PubMed Close
,
Rudolf Bauer Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria

Search for other papers by Rudolf Bauer in
Google Scholar
PubMed Close
, and
Roswitha Pfragner Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Graz, Austria

Search for other papers by Roswitha Pfragner in
Google Scholar
PubMed Close

). In glioblastoma cells U87MG, various shikonin derivatives have been reported to have cytotoxic properties with IC 50 values ranging from 3.61 µM to 51.97 µM ( 30 ). In combination with the tyrosine kinase inhibitor erlotinib, however, synergistic

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-16-0105
Volume/Issue:
Volume 6: Issue 2
Open access
Marra Jai Aghajani Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia

Search for other papers by Marra Jai Aghajani in
Google Scholar
PubMed Close
,
Tara Laurine Roberts Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia

Search for other papers by Tara Laurine Roberts in
Google Scholar
PubMed Close
,
Tao Yang School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Saint Vincent’s Clinical School, UNSW Sydney, Sydney, Australia
SydPath, Saint Vincent’s Hospital, Sydney, Australia

Search for other papers by Tao Yang in
Google Scholar
PubMed Close
,
Charles Eugenio McCafferty Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia

Search for other papers by Charles Eugenio McCafferty in
Google Scholar
PubMed Close
,
Nicole J Caixeiro Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Centre for Oncology Education and Research Translation (CONCERT), Liverpool, New South Wales, Australia

Search for other papers by Nicole J Caixeiro in
Google Scholar
PubMed Close
,
Paul DeSouza Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia

Search for other papers by Paul DeSouza in
Google Scholar
PubMed Close
, and
Navin Niles Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Department of Head & Neck Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia

Search for other papers by Navin Niles in
Google Scholar
PubMed Close

survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib . Lung Cancer 2016 100 . ( https://doi.org/10.1016/j.lungcan.2016.08.001 ) 27597284 28 Zhao J Zhang P Wang J Xi Q Zhao X Ji M Hu G

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0210
Volume/Issue:
Volume 8: Issue 7
Open access
E T Aristizabal Prada Department of Internal Medicine IV, Campus Grosshadern, University-Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by E T Aristizabal Prada in
Google Scholar
PubMed Close
and
C J Auernhammer Department of Internal Medicine IV, Campus Grosshadern, University-Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by C J Auernhammer in
Google Scholar
PubMed Close

NET cell lines (BON1, QGP1, KRJ-I and LCC-18) ( 84 ). Combination of mTORC1 and EGFR inhibition Everolimus exhibited synergistic effects in combination with the EGFR inhibitor erlotinib on large-cell NETs and bronchial NETs with an activated

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-17-0286
Volume/Issue:
Volume 7: Issue 1
Open access
Sofia S Pereira Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
Endocrine, Cardiovascular & Metabolic Research, Department of Anatomy, Multidisciplinary Unit for Biomedical Research (UMIB), Instituto de Ciências Biomédicas Abel Salazar, University of Porto (ICBAS/UP), Porto, Portugal

Search for other papers by Sofia S Pereira in
Google Scholar
PubMed Close
,
Mariana P Monteiro Endocrine, Cardiovascular & Metabolic Research, Department of Anatomy, Multidisciplinary Unit for Biomedical Research (UMIB), Instituto de Ciências Biomédicas Abel Salazar, University of Porto (ICBAS/UP), Porto, Portugal

Search for other papers by Mariana P Monteiro in
Google Scholar
PubMed Close
,
Sonir R Antonini Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other papers by Sonir R Antonini in
Google Scholar
PubMed Close
, and
Duarte Pignatelli Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
Department of Endocrinology, Hospital S. João, Porto, Portugal

Search for other papers by Duarte Pignatelli in
Google Scholar
PubMed Close

xenographs DZNep EZH2 (histone modifier) inhibitor BCL2 , BCL-XL and BIRC5 expression/Caspase 3 activity assay/TUNEL assay ACC cell line NCI-H295R (145) Erlotinib and NVP-AEW541 combination EGFR and IGF1R inhibitor Annexin V

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-19-0114
Volume/Issue:
Volume 8: Issue 5
Open access